ESCORTS-LIMITED
9.11.2016 16:25:05 CET | Business Wire | Press release
Farmtrac, one of the world’s leading tractor companies based out of Poland, today announced the launch of a new range of FT 6080 Pro and FT 6090 Pro Farmtrac tractors in 80 & 90 HP category simultaneously in Italy and Mexico at EIMA, International Exposition of Machinery for Agriculture and Gardening, Bologna, and at Expo Agroalimentaria Guanajuato, Irapuato, respectively. Aligned to Farmtrac's pedigree of classic, simple and efficient farm machines, these new FT 6080 Pro and FT 6090 Pro tractors are technology marvels with value for money for farmers worldwide.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161109005758/en/
Farmtrac has been manufacturing tractors in Poland for the world's farmers for more than 15 years now and caters to farmers across 15 countries within Europe and 54 countries globally, with annual production volume close to 70,000 tractors per annum. The Farmtrac tractors conform to stringent European norms in every aspect with the new CRDi engine and transmission designs, most advanced in their category. Custom manufactured for world farmers, Farmtrac FT 6080 Pro & FT 6090 Pro tractors are cost-efficient, high-end machines with state of the art technology. These tractors have the edge of unchallenged fuel economy backed by zero RPM drop in engine, lifting capacity up to 3000 kg, cold start ability at -15˚ C and special features for paddy cultivation.
Speaking on the occasion, Ravi Menon, Chief Executive Officer, Escorts Agri Machinery, said, “Our brand Farmtrac has always aimed at providing farmers with advanced agricultural equipment, which have the best value for money. With our new Global Transformation Vision 2020, we wish to change the way farmers globally perceive farming, by producing tractors with value proposition of fuel efficiency and cost-effectiveness.”
Rajiv Wahi, Head – International Business, Escorts Agri Machinery, elaborated further saying, “The new range of Farmtrac tractors is positioned to fill the often perceived market gap in the category. We have strengthened our global networks to effectively cater to farmer demands in newer geographies. With the Farmtrac product range, we aim to provide a Simple, Classic and Efficient range of Tractors to farmers in Europe and America.”
About Farmtrac Europe
The Farmtrac Poland plant is a 100% subsidiary of Escorts with installed manufacturing capacity of 3000 tractors per annum. The products are both designed and developed in this state of the art unit catering to the demand of 15 countries of the European Union. Meeting all European standards, its current offerings includes 20 different types and varieties of tractor. With a reputation for durability, Farmtrac tractors offer an unbeatable value of its product which is demonstrated by the use of the best components in the world assembled by highly-skilled engineers.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161109005758/en/
Contact:
Escorts Limited
Sharad Gupta
Group Head, Corporate
Brand Communications
sharad.gupta@escorts.co.in
or
Torque
Communications Pvt Ltd.
Rajat Gupta
+91 9953500503
rajat@torquemail.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom